-
Citizens Raises OptimizeRX (OPRX) PT to $23 on Subscription Growth, Margin Potential
-
OptimizeRx names new executives in leadership restructuring
-
OptimizeRX (OPRX) PT Raised to $20 at Citizens JMP
-
Optimizerx Corporation (OPRX) Tops Q2 EPS by 22c
-
Optimizerx Corporation (OPRX) Appoints CEO Steve Silvestro to its Board
-
Simulmedia and OptimizeRx (OPRX) partner to enable self-serve availability of MNT audiences
-
OptimizeRX (OPRX) PT Raised to $16 at Stifel
-
OptimizeRX (OPRX) PT Raised to $14 at Citizens JMP
-
Optimizerx Corporation (OPRX) Tops Q1 EPS by 20c ; Offers Guidance
-
Optimizerx Corporation (OPRX) Files $75M Mixed Shelf
-
Optimizerx Corporation (OPRX) Confirms Receipt of Notice of Director Nominations
-
Optimizerx Corporation (OPRX) Appoints Stephen Silvestro as CEO
-
RBC Capital Downgrades OptimizeRX (OPRX) to Sector Perform
-
Lake Street Capital Markets Reiterates Buy Rating on OptimizeRX (OPRX)
-
Stifel Reiterates Buy Rating on OptimizeRX (OPRX) Amid CEO Departure
-
OptimizeRX (OPRX) PT Lowered to $13 at B.Riley
-
Optimizerx Corporation (OPRX) Announces CEO Change
-
OptimizeRX (OPRX) PT Lowered to $11 at Lake Street Capital Markets
-
Optimizerx Corporation (OPRX) Tops Q3 EPS by 6c
-
Optimizerx Corporation (OPRX) Continues to Expand its Strategic Relationship with a Top-Tier Pharma Client via a Multi-Brand, Multi-Solution Investment Commitment with Over $10M In-Year Total Value
-
OptimizeRX (OPRX) PT Lowered to $14 at RBC Capital
-
Optimizerx Corporation (OPRX) Delivers AI-Guided Privacy-Compliant Platform for Pharmaceutical Brand Marketing Amid Evolving Consumer Privacy Legislation

